Skip to main content
Dryad

Inflammatory cells and remodeling in bronchial biopsies from COPD patients and controls

Eagan, Tomas1; Nielsen, Rune2; Haaland, Ingvild2; Husebø, Gunnar1; Lehmann, Sverre1; Ward, Jon3; Wilson, Susan3

Research facility: Haukeland University Hospital
Published Oct 23, 2025 on Dryad. https://doi.org/10.5061/dryad.3n5tb2rvf

Data files

Oct 23, 2025 version files 147.55 KB

Click names to download individual files

Abstract

The understanding of inflammation and remodeling in the bronchial wall of COPD patients with varying disease severity remains incomplete. 35 healthy controls and 47 volunteer COPD patients underwent bronchoscopy with bronchoalveolar lavage (BAL) and sampling by endobronchial biopsies in 2014-2015 as part of the MicroCOPD Study. Biopsies were embedded in glycol methyl acrylate (GMA) resin and examined by immunohistochemistry and staining for enumeration of CD3+, CD4+, CD8+, CD20+, CD68+, EG2+, and NE+ inflammatory cells, as well as endothelial cells (EN4) and smooth muscle actin (SMA). Mucus cells were stained by periodic acid-schiff (PAS) and toluidine blue to visualize the reticular basement membrane (RBM). The number of macrophages and eosinophils was higher, and vascularity increased in the submucosa in COPD patients compared with healthy controls. In healthy smokers, there were lower numbers of lymphocytes (CD3+, CD4+, CD8+, CD20+) than in never smokers. However, COPD patients with GOLD I/II had higher numbers of eosinophils and larger smooth muscle area compared with GOLD III/IV. COPD exacerbations the last year, blood eosinophils, and use of inhaled corticosteroids did not affect levels of inflammation or remodeling. Smoking alters inflammation in healthy controls, while specific patterns of macrophages, eosinophils, and vascularity distinguish COPD from non-COPD in bronchial biopsies.